Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,671 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Breast Diseases Clear all
No Longer Available No phase listed Expanded access

A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

NCT01120561
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
trastuzumab-MCC-DM1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
15
States / cities
Highland, California • Stockton, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 8, 2026, 11:03 AM EDT
Not listed Phase 1 Interventional

Cardiac Safety Assessment Study of Picoplatin in Solid Tumors

NCT00710697
View directory record Official record
Conditions
Solid Tumors
Interventions
Picoplatin
Drug
Lead sponsor
Poniard Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Effects of Creatine Supplementation in Breast Cancer Survivors

NCT04207359
View directory record Official record
Conditions
Breast Cancer, Chemotherapy Effect, Muscle Weakness, Muscle Loss, Exercise
Interventions
Creatine
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 8, 2026, 11:03 AM EDT
Completed No phase listed Observational

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

NCT03892096
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer
Interventions
Blood-based cell-free cfDNA qPCR assay
Diagnostic Test
Lead sponsor
Cadex Genomics
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
11
States / cities
Little Rock, Arkansas • Sunnyvale, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 8, 2026, 11:03 AM EDT
Recruiting Phase 2 Interventional

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

NCT06897488
View directory record Official record
Conditions
Breast Cancer
Interventions
Adjuvant Radiotherapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Individuals on Hormone Therapy Breast Cancer Screening Pilot

NCT06383026
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Cancer Screening, Survey/Interview, Focus Group
Diagnostic Test · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
30 Years to 75 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

AirXpanders AeroForm Tissue Expander System for Breast Reconstruction

NCT02504424
View directory record Official record
Conditions
Breast Cancer
Interventions
AeroForm Tissue Expander
Device
Lead sponsor
AirXpanders, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
8
States / cities
Greenbrae, California • San Jose, California • Fort Lauderdale, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 8, 2026, 11:03 AM EDT
Active, not recruiting Phase 1 Interventional

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879
View directory record Official record
Conditions
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Interventions
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine
Drug
Lead sponsor
Enliven Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 8, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional Results available

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

NCT02000596
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Chemotherapy with Eribulin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 8, 2026, 11:03 AM EDT
Recruiting Phase 1 Interventional

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

NCT07361562
View directory record Official record
Conditions
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
Interventions
CGT4255
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Not yet recruiting Not applicable Interventional

PRehabilitation Intervention to Modify Eating for Breast Cancer Patients (PRIME)

NCT07638150
View directory record Official record
Conditions
Breast Cancer
Interventions
Mediterranean Diet
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Withdrawn No phase listed Observational

Breast Cancer BRCA1 Carriers: a Pilot Study

NCT05062174
View directory record Official record
Conditions
BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
Mifepristone 200 MG, Prophylactic mastectomy
Drug · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Phase 1Phase 2 Interventional

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

NCT01386580
View directory record Official record
Conditions
Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, Malignant Glioma
Interventions
2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks, 2B3-101 50 mg/m2 every 3 weeks
Drug
Lead sponsor
BBB-Therapeutics B.V.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Sep 8, 2026, 11:03 AM EDT
Completed No phase listed Observational

Optional Sub-study to Intraoperative Imaging With ICG Registry

NCT02651246
View directory record Official record
Conditions
Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
Interventions
data collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 8, 2026, 11:03 AM EDT
Recruiting Phase 1 Interventional

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

NCT06488378
View directory record Official record
Conditions
Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
Interventions
Axatilimab, Olaparib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Breast Tumor Oxygenation During Exercise

NCT02340468
View directory record Official record
Conditions
Breast Tumor
Interventions
diffuse optical spectroscopy
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years to 70 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

NCT01624220
View directory record Official record
Conditions
Spinal Tumor
Interventions
Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation, Questionnaires
Radiation · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Breast Milk: Influence of the Micro-transcriptome Profile on Atopy in Children Over Time

NCT04017520
View directory record Official record
Conditions
Atopy, Atopic Dermatitis Eczema, Wheezing, Food Allergy in Infants
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
0 Days to 7 Days
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breast and Cervical Cancer Educational Intervention for Latinas in Western New York

NCT01760850
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer
Interventions
educational intervention, questionnaire administration
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 8, 2026, 11:03 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Wearable Ultrasound Patch for Breast Imaging

NCT07186491
View directory record Official record
Conditions
Breast Cancer, Breast Abnormalities, Breast Lesion, Breast Asymmetry
Interventions
Wearable Ultrasound Patch
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Not applicable Interventional

A Mind-body Intervention to Improve Body and/or Self Image

NCT02531997
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions
Hypnotic Relaxation Therapy, Progressive Muscle Relaxation
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 8, 2026, 11:03 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

NCT06065059
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
Interventions
TNG348, Olaparib
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Denver, Colorado • Orange City, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 8, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

NCT02871115
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, GI Cancer
Interventions
Pharmacy Intervention, Usual Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
65 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 8, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional Results available

Brain Mets - Capecitabine Plus Sunitinib and WBRT

NCT00570908
View directory record Official record
Conditions
Breast Cancer
Interventions
sunitinib, capecitabine, WBRT
Drug · Radiation
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 8, 2026, 11:03 AM EDT